Akero Therapeutics (AKRO)

Company Profile

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.

Company profile

Ticker

AKRO

Exchange

NASDAQ

Website

akerotx.com

CEO

Andrew Cheng

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Abbott Laboratories • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

SEC CIK

0001744659

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Akero Securities Corporation ...

AKRO stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$60.50

Low target

$59.00

High target

$62.00

Latest filings (excl ownership)

View all

8-K

Results of Operations and Financial Condition

5 Jun 23

8-K

Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock

17 May 23

424B5

Prospectus supplement for primary offering

15 May 23

Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

15 May 23

ARS

2022 FY

Annual report to shareholders

28 Apr 23

Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH

29 Mar 23

S-8

Registration of securities for employees

17 Mar 23

8-K

Entry into a Material Definitive Agreement

17 Mar 23

Latest ownership filings

View all

ADAGE CAPITAL PARTNERS GP, L.L.C.

Notice of proposed sale of securities

3 Apr 23

William Richard White

Financial summary

Financial statements Chart AKRO financial data

Quarter (USD)	Mar 23	Dec 22	Sep 22	Jun 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	257.99 mm	257.99 mm	257.99 mm	257.99 mm	257.99 mm	257.99 mm
Cash burn (monthly)	(no burn)	(no burn)	9.58 mm	9.82 mm	8.21 mm	7.86 mm
Cash used (since last report)	n/a	n/a	21.58 mm	22.11 mm	18.48 mm	17.69 mm
Cash remaining	n/a	n/a	236.42 mm	235.88 mm	239.51 mm	240.31 mm
Runway (months of cash)	n/a	n/a	24.7	24.0	29.2	30.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2022

AKRO institutional ownership history Ownership history

97.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	121	108	+12.0%
Opened positions	24	13	+84.6%
Closed positions	11	8	+37.5%
Increased positions	40	35	+14.3%
Reduced positions	29	26	+11.5%

13F shares	Current	Prev Q	Change
Total value	1.18 bn	773.49 mm	+53.0%
Total shares	49.06 mm	44.79 mm	+9.5%
Total puts	0.00	23.00 k	EXIT
Total calls	11.30 k	0.00	NEW
Total put/call ratio	–	Infinity	–

Largest owners	Shares	Value	Change
Skorpios Trust	4.91 mm	$46.38 mm	0.0%
JHG Janus Henderson	3.07 mm	$28.99 mm	-8.9%
venBio Global Strategic Fund	3.03 mm	$106.05 mm	0.0%
Alkeon Capital Management	2.62 mm	$24.76 mm	+8.3%
PFE Pfizer	2.53 mm	$30.71 mm	NEW
venBio Global Strategic Fund II	2.32 mm	$67.76 mm	0.0%
Point72 Asset Management	2.30 mm	$21.74 mm	+24.5%
Atlas Venture Life Science Advisors	2.23 mm	$21.10 mm	0.0%
venBio Partners	2.17 mm	$20.52 mm	0.0%
BLK Blackrock	2.09 mm	$19.76 mm	+10.3%

Largest transactions	Shares	Bought/sold	Change
PFE Pfizer	2.53 mm	+2.53 mm	NEW
Wellington Management	702.48 k	-1.53 mm	-68.5%
Marshall Wace	1.01 mm	+1.01 mm	NEW
GS Goldman Sachs	1.86 mm	+770.92 k	+70.6%
STT State Street	492.85 k	-746.27 k	-60.2%
Versant Venture Management	0.00	-617.73 k	EXIT
Millennium Management	520.77 k	+455.53 k	+698.2%
Point72 Asset Management	2.30 mm	+453.00 k	+24.5%
Yiheng Capital Management	1.88 mm	+329.71 k	+21.2%
JHG Janus Henderson	3.07 mm	-300.35 k	-8.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

AKRO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Jun 23	Cheng Andrew	Common Stock	Sell	Dispose S	No	Yes	45.897	400	18.36 k	409,293
1 Jun 23	Cheng Andrew	Common Stock	Sell	Dispose S	No	Yes	45.2562	20,686	936.17 k	409,693
1 Jun 23	Cheng Andrew	Common Stock	Sell	Dispose S	No	Yes	44.1752	3,914	172.90 k	430,379
1 Jun 23	Cheng Andrew	Common Stock	Option exercise	Acquire M	No	Yes	6.36	3,670	23.34 k	434,293
1 Jun 23	Cheng Andrew	Common Stock	Option exercise	Acquire M	No	Yes	0.615	21,330	13.12 k	430,623
1 Jun 23	Cheng Andrew	Stock Option Common Stock	Option exercise	Dispose M	No	Yes	6.36	3,670	23.34 k	140,000
1 Jun 23	Cheng Andrew	Stock Option Common Stock	Option exercise	Dispose M	No	Yes	0.615	21,330	13.12 k	64,538
1 May 23	Cheng Andrew	Common Stock	Sell	Dispose S	No	Yes	45.5045	3,477	158.22 k	409,293
1 May 23	Cheng Andrew	Common Stock	Sell	Dispose S	No	Yes	45.0049	21,523	968.64 k	412,770
1 May 23	Cheng Andrew	Common Stock	Option exercise	Acquire M	No	Yes	0.615	25,000	15.38 k	434,293